Coronary artery spasm - Clinical features, pathogenesis and treatment

Area of Science:

• Cardiology
• Genetics
• Biochemistry

Background:

• Coronary artery spasm (CAS) is a significant factor in ischemic heart disease, manifesting as angina, myocardial infarction, and sudden death, particularly between midnight and early morning.
• CAS prevalence is higher in East Asian populations, often correlating with aldehyde dehydrogenase 2 (ALDH2) deficiency (ALDH2*2 genotype) and alcohol flushing.
• ALDH2 plays a crucial role in detoxifying acetaldehyde and other harmful aldehydes from lipid peroxidation and smoking, protecting cells from oxidative damage.

Purpose of the Study:

• To elucidate the role of ALDH2 deficiency and oxidative stress in the pathogenesis of coronary artery spasm.
• To identify genetic risk factors and underlying mechanisms contributing to CAS.
• To highlight effective therapeutic strategies for CAS.

Main Methods:

• Review of existing literature on CAS, ALDH2 genetics, oxidative stress, and endothelial function.
• Analysis of the association between ALDH2*2 genotype, alcohol flushing, and CAS prevalence.
• Examination of the molecular pathways involved in CAS, including RhoA/ROCK activation and calcium sensitivity.

Main Results:

• ALDH2 deficiency is a key risk factor for CAS, particularly in East Asians.
• Smoking and genetic polymorphisms (ALDH2*2, eNOS, PON1, IL-6) are identified risk factors for CAS.
• Oxidative stress, endothelial dysfunction, and chronic inflammation contribute to CAS pathogenesis via RhoA/ROCK pathway activation, increasing coronary smooth muscle Ca2+ sensitivity.

Conclusions:

• ALDH2 deficiency and associated oxidative stress are critical in CAS development.
• Understanding genetic predispositions and molecular mechanisms is vital for CAS management.
• Calcium channel blockers are a primary and effective treatment for CAS by inhibiting intracellular calcium entry.